THEILACIDE 50MG/ML INJECTION

Indications

• Treatment of Babesiosis in cattle
• Management of other protozoal infections in veterinary medicine

Dosage

Children: Refer to specific veterinary guidelines for dosing in young animals, as pediatric doses depend on age, weight, and species.

Adults: Refer to specific veterinary guidelines for dosing in adult animals, as dosage may vary based on species and condition.

Mechanism of action

Buparvaquone acts by inhibiting the mitochondrial electron transport chain in protozoa, interfering with their oxidative phosphorylation process. This inhibition leads to a decrease in ATP production, essential for the survival and replication of the protozoa.

Pharmacodynamics

Buparvaquone demonstrates selective toxicity towards protozoa due to its specific interaction with the mitochondrial respiratory chain. The drug exhibits a concentration-dependent effect, with higher concentrations leading to more significant inhibition of protozoal growth. Its efficacy is influenced by the metabolic activity of the target organism.

Pharmacokinetics

Buparvaquone is well-absorbed following oral administration, with peak plasma concentrations typically occurring within a few hours. It has a high volume of distribution and is extensively metabolized in the liver. The primary route of elimination is via feces, with a minor portion excreted in urine. The half-life of buparvaquone is variable, depending on the species and dosage form.

Pregnancy

The safety of buparvaquone in pregnancy has not been established. Caution is advised.

Breast-feeding

It is not known whether buparvaquone is excreted in human milk. Caution is advised.

Storage

Store at room temperature, away from light and moisture. Keep out of reach of children.

Formulations

• {'name': 'buparvaquone', 'molecular_formula': 'C21H26O3'}